Aine Clements, MD
Gynecologic Oncology · Columbus, OHNPI 1225294689
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $8,905 of the $10,607 with a category attached, or 84.0%. AstraZeneca accounts for 92.3% of it on its own, with 5 other manufacturers making up the rest. Reporting peaked in 2019 at $7,928 and has fallen 97.9% since, to $167 in 2025.
Across 20 payments — averaging $530.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$10K
- Tesaro, Inc.$366
- Astellas Pharma US Inc$125
- Tempus AI, Inc$124
- GSK$118
- AbbVie$87
Across 65 payments — averaging $16,501 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Tesaro, Inc.$678K
- GSK$367K
- Eisai Inc.$27K
What the payments were for
- Consulting fees$8,90584%
- Travel & lodging$4905%
- Food & beverage$1,16911%
- Education$430%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 13 | $9,788 |
| Tesaro, Inc. | 3 | $366 |
| Astellas Pharma US Inc | 1 | $125 |
| Tempus AI, Inc | 1 | $124 |
| GSK | 1 | $118 |
| AbbVie | 1 | $87 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$10,607 in reported general payments places this provider in the 75th percentile of 62 gynecologic oncology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 27 | $15,920 |
| Megestrol Acetate | 24 | $1,491 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 17 | $561 |
| Clobetasol Propionate | 11 | $463 |
| Letrozole | 28 | $377 |
| Oxycodone Hcl | 19 | $117 |
Paid to pharmacies, not to this prescriber.
Other gynecologic oncology in Columbus
- Luis VaccarelloColumbus$12K
- Kellie RathColumbus$5K
- Blair SmithColumbus$3K
- Rhiannon ByronColumbus$588
- Corinne CaloColumbus$435
- Amy HarperColumbus$362
- Vidhya KrishnanColumbus$95
- David OmalleyHilliard$650K
- Thomas HerzogCincinnati$585K
- Floortje BackesHilliard$181K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.